瑞士前列腺癌患者的真实世界治疗模式与医疗费用——基于理赔数据的分析
本研究利用瑞士一家主要法定医疗保险机构的纵向个体理赔数据,基于所接受的治疗识别接受治疗的前列腺癌患者,描述2014至2018年五年间局部与转移性前列腺癌患者的医疗服务利用、治疗路径及从医疗系统角度计算的费用。
要点
- 共纳入5591例前列腺癌患者,其中3502例接受雄激素剥夺治疗(ADT)。
- 接受ADT的患者中9.5%联合多西他赛,11.0%联合阿比特龙酯。
核心结论
- 本研究中大多数前列腺癌患者是基于ADT使用而被识别的。
- 2018年瑞士前列腺癌医疗费用占医疗总支出的0.45%,转移性前列腺癌治疗约占三分之二。
研究设计与样本
- 研究使用瑞士一家主要法定医疗保险机构常规收集的纵向个体理赔数据。
- 因理赔数据缺乏诊断编码,依据所接受的治疗识别接受治疗的前列腺癌患者,并分别描述局部与转移性前列腺癌患者的医疗服务利用和治疗路径。
- 费用从医疗系统角度计算,研究期间为2014至2018年五年。
主要发现
- 共5591例前列腺癌患者符合纳入标准。
- 2014至2018年间,1741例患者因局部或转移性前列腺癌接受门诊放疗,1579例接受根治性前列腺切除术。
- 3502例患者接受雄激素剥夺治疗(ADT),其中9.5%联合多西他赛,11.0%联合阿比特龙酯。
- 多西他赛是最常用的化疗药物(一线;n=413,占所有化疗患者的78.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PC) is the most prevalent cancer in men in Switzerland. However, evidence on the real-world health care use of PC patients is scarce. The aim of this study is to describe health care utilization, treatment patterns, and medical costs in PC patients over a period of five years (2014-2018). METHOD: We used routinely collected longitudinal individual-level claims data from a major provider of mandatory health insurance in Switzerland. Due to the lack of diagnostic coding in the claims data, we identified treated PC patients based on the treatments received. We described health care utilization and treatment pathways for patients with localized and metastatic PC. Costs were calculated from a health care system perspective. RESULTS: A total of 5591 PC patients met the inclusion criteria. Between 2014 and 2018, 1741 patients had outpatient radiotherapy for localized or metastatic PC and 1579 patients underwent radical prostatectomy. 3502 patients had an androgen deprivation therapy (ADT). 9.5% of these patients had a combination therapy with docetaxel, and 11.0% had a combination with abiraterone acetate. Docetaxel was the most commonly used chemotherapy (first-line; n = 413, 78.4% of all patients in chemotherapy). Total medical costs of PC in Switzerland were estimated at CHF 347 m (95% CI 323-372) in 2018. CONCLUSION: Most PC patients in this study were identified based on the use of ADT. Medical costs of PC in Switzerland amounted to 0.45% of total health care spending in 2018. Treatment of metastatic PC accounted for about two thirds of spending.
引用
- Stucki M, Dosch S, Gnädinger M, et al. Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis. Eur J Cancer. 2024. PMID: 38678761. doi:10.1016/j.ejca.2024.114072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。